This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Good morning and welcome to Premier's Fiscal 2025 First Quarter Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ben Krasinski, Senior Director, Investor Relations. Please go ahead.
spk10: Thank you and welcome to Premier's Fiscal 2025 First Quarter Conference Call. Our speakers this morning are Mike Alkire, Premier's President and CEO, and Craig McCassen, our Chief Administrative and Financial Officer. Before we get started, I want to remind everyone that our earnings release and the supplemental presentation accompanying this call are available in the Investors section of our website at .premierinc.com. Please be advised that management's remarks today contain certain forward-looking statements, such as statements regarding our strategies, plans, prospects, expectations, and future performance, and actual results could differ materially from those discussed today. These forward-looking statements speak as of today, and we undertake no obligation to update them. Factors that might affect future results are discussed in our filings with the SEC, including our most recent Form 10-K and our Form 10-Q for the quarter, which we expect to file soon. We encourage you to review the detailed forward-looking statement and risk factor disclosures in these reports. Also, during this presentation, we will refer to adjusted and other non-GAAP financial measures, including free cash flow, to evaluate our business. Information on why we use these measures in addition to GAAP financial measures and reconciliations of these measures to our GAAP financial measures are included in our earnings release and in the appendix of the supplemental presentation accompanying this call. Information on our non-GAAP financial measures will also be included in our Form 10-Q for the quarter and our earnings Form 8-K, both of which we expect to file soon. I will now turn the call over to Mike Alcar.
spk07: Good morning, everyone, and thank you for joining us today. I'm pleased to report that fiscal 2025 first quarter results slightly exceeded our expectations for total net revenue and profitability, giving us confidence in reaffirming our fiscal 2025 guidance. From a segment perspective, supply chain services revenue exceeded our expectations, while performance services revenue fell slightly short of what we anticipated for the quarter. Craig will provide more details later in the call. In addition, we returned capital to stockholders through our quarterly cash dividend and the common shares during the quarter under our previously announced $1 billion share repurchase authorization. Today marks Election Day in the United States. As a reminder, our strategies are designed to be less reliant on political and regulatory influences and more concentrated on addressing the core challenges faced by our members and other customers. Our strategies and member relationships are founded on the understanding that improving healthcare delivery for patients relies on reducing costs and improving outcomes through technologies. Regardless of the outcome, our commitment to improving the health of communities we serve remains unwavering. Turning to our business, momentum continues to grow in the market for Premier's technology-driven supply chain strategy. By collaborating closely with our members and leveraging technology and services, we're identifying additional cost savings opportunities for our members while enhancing contract penetration in our group purchasing programs. Our strong member relationships have driven progress in contract renewals, which are also opening the door for us to have deeper and more strategic, data-driven discussions with members on opportunities for improvement. Our high renewal rate reflects our commitment to collaboration and the trust we've built with our members over the years. In addition, we continue to partner with our members, manufacturers, government agencies, and other stakeholders to help mitigate the impact that recent hurricanes have had on supply chains and hospital operations across the American communities. With these challenges, the need for Premier to support our member hospitals and health systems remains at an all-time high. Premier's response to each disaster reinforces our commitment to enhancing the overall health care system's predictability, resilience, and response through technology enablement. These trying times have been particularly challenging for our health system members. Our job is to minimize the impact to be a vital ally in building the future of health care. Turning to our performance services business, we continue to focus on opportunities to utilize our robust data and AI-enabled technology to deliver unparalleled insights and efficiencies for our members and other customers. For example, we were pleased to renew and extend our engagement with a government agency that leverages Premier's data set and proprietary performance improvement methodologies to scale improvements in maternal and infant health outcomes in hospitals across the nation. We also expanded our partnership with one of the top pharma companies in the world to include additional real-world evidence and observational research related to their innovations in Alzheimer's disease. This work underscores our unique differentiation in the marketplace that facilitates better, smarter, faster health care, better with national scale, smarter with real-time actionable insights, and faster with AI-enabled technologies. We also continue to advance our sustainability efforts. A few weeks ago, we published our 2024 Sustainability Report and Climate Resilience Plan, highlighting our many practices and initiatives aimed at improving health care, operating responsibly, and positively impacting communities. Before I hand it over to Craig, I want to take a moment to express our gratitude for his 27 years of service. He has been an incredible leader for Premier and exemplifies integrity in all he does. We wish him the best in his retirement. We also look forward to introducing you to our new Chief Administrative and Financial Officer Glenn Coleman during our second quarter earnings call in February. Craig?
spk09: Thanks, Mike. I truly appreciate your kind words. First, I would like to note that resulting from our divestiture of the S2S Global Direct Sourcing business, unless otherwise indicated, all results discussed during this call reflect our continuing operations. In addition, as the divestiture process for the Contigo Health business remains ongoing, actual results will continue to include contributions from that business, although it will be excluded from guidance given the expectation that it will be divested and moved to discontinued operations. As such, we have included a table in our earnings release and supplemental presentation that reconciles the impact of the Contigo Health business on certain financial measures for the quarter. Now turning to our fiscal 2025 first quarter results, total net revenue of $248.1 million decreased 8% from the prior year period. In our supply chain services segment, lower net administrative fees revenue was driven by an expected increase in the aggregate blended member fee share to the low 60% level in the quarter. However, gross administrative fees revenue was better than expected, resulting from ongoing growth in member purchasing as we continue to drive higher penetration of our existing member spend. To provide an update, the group of GPO members that were part of the August 2020 restructure represent approximately 70% of our total gross administrative fees. As of September 30th, we have addressed members representing approximately 55% of this group's associated gross administrative fees. We currently plan to address and finalize additional member renewals during the current fiscal year that would result in over three-fourths of this group's gross administrative fees being through the renewal process by the end of fiscal 2025, with the remainder occurring in fiscal 2026 and 2027. Additionally, we experience growth in our other supply chain services revenue driven by new agreements in our supply chain co-management business, where members continue to express interest in leveraging Premier's expertise to help manage their -to-end supply chain operations. In our performance services segment, the revenue decline was mainly driven by lower demand in the consulting business compared to the prior year period, continued pressure in the Contigo health business, and timing of engagements in the applied sciences business. Turning to profitability, GapNet income was $72.9 million for the quarter, which benefited from a $57 million non-operating gain from the derivative lawsuit settlement in the current year period. Total adjusted EBITDA of $62.4 million was better than expected in the quarter, resulting from our GPO performance. However, compared to the prior year period, adjusted EBITDA declined due to the following factors. First, the supply chain services adjusted EBITDA declined mainly due to the decrease in net administrative fees revenue as a result of the expected increase in fee share, as well as additional investments in the supply chain co-management business to support ongoing growth. And second, performance services adjusted EBITDA decreased mainly due to the decline in revenue in the consulting and applied sciences businesses. Adjusted net income decreased primarily as a result of the same factors that impacted adjusted EBITDA, partially offset by a decrease in our effective income tax rate in the current year period. Adjusted earnings per share was affected by the same factors as well as completion of the $400 million accelerated share repurchase transaction in July. Then, in August and September, we repurchased an additional $58 million of shares in the open market. As of September 30th, we have repurchased and retired nearly 23 million Class A common shares under the $1 billion share repurchase authorization. From a liquidity and balance sheet perspective, cash flow from continuing operations for the fiscal 2025 first quarter of $80 million increased from the prior year period primarily due to cash received from the derivative lawsuit settlement of $57 million in the current year period, partially offset by higher performance-related compensation payments resulting from better fiscal 2024 performance against expectations than in the prior year period where performance was lower than expectations. Free cash flow for fiscal 2025 first quarter of $16.2 million increased from the prior year period primarily due to the same factors that impacted cash flow from operations as well as a decrease in purchases of property and equipment. These were partially offset by a full quarter of cash payments in the current year period to OMEA related to the sale of future revenue compared to a partial quarter in the prior year due to timing of the sale of the non-healthcare GP operations in fiscal 2024. As a reminder, free cash flow is typically lowest in the first quarter since our fiscal year ends in June and payment of certain expenses including annual performance-related compensation occurs in the first quarter. Cash and cash equivalents totaled $87 million as of September 30, 2024 compared with $125.1 million as of June 30, 2024. The decrease was primarily driven by the use of cash for share repurchases. Our five-year $1 billion revolving credit facility continued to have no balance as of the end of the quarter. With respect to the sale of the non-healthcare GPO operations, we received the final payment of $42.3 million in the first quarter resulting in cumulative proceeds of $723.8 million. With respect to capital deployment, we continue to remain disciplined and focused on taking a balanced approach while also remaining focused on return of capital to stockholders in the near term. As a reminder, in August we announced that our board approved execution of another share repurchase of $200 million under our $1 billion share repurchase authorization. We continue to repurchase shares under that program and following completion, our board and management team will evaluate the remaining $400 million available under the current $1 billion authorization. This augmented our quarterly cash dividend which totaled $21.3 million in the first quarter of fiscal 2025. In addition, our board recently declared a dividend of $0.21 per share payable in December. We will continue to evaluate opportunities to invest in organic growth and potential acquisitions to differentiate our core offerings in the marketplace. Turning to our fiscal 2025 guidance, based on performance for the first three months of the year, we are reaffirming the guidance that we introduced on our earnings call in August. Please note that while we have begun to repurchase shares under the $200 million share repurchase program, we are not planning to update adjusted earnings per share guidance until we have completed the program. From a cadence perspective, we currently expect the following. In our GPO business, we expect a sequential decline in net administrative fees revenue in the second quarter as we continue to work through the ongoing contract renewal process. In the back half of the year, we expect relatively comparable performance with the first half as the impact of contract renewals is offset by the ongoing impact of residual purchasing from departed members. In our performance services business, and based on the current expectations for the timing of engagements, we still anticipate revenue will be more back half-weighted with the second quarter at or slightly above the first quarter. As a reminder, due to the timing and magnitude of enterprise license agreements and certain consulting arrangements, there may be periodic variability in the recognition of the revenue and profitability associated with these engagements between quarters. From a profitability perspective, we continue to expect adjusted EBITDA and adjusted earnings per share to be more back half-weighted mainly due to the revenue cadence in the performance services business. In addition, we expect a sequential decline in the second quarter mainly due to the impact of the GPO contract renewal process. Before I conclude, I would like to remind everyone that this will be my last earnings call with Premier as I am retiring in December. It's truly been an honor to work with such an amazing team, be part of our strong culture, and to contribute to Premier's mission to improve the health of communities. I'd also like to thank the financial community for their collaboration over the years. It has indubitably been a pleasure to work with you, and I believe you will be in good hands going forward as I have full confidence in Glen and the rest of the team. We appreciate your time today and will now open the call for questions.
spk06: We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. At this time, we will pause momentarily to assemble our roster. The first question comes from Eric Percher with Nefron Research. Please go ahead. Thank
spk02: you, and Craig, I'll wish you luck and appreciate that you managed to fit the question into the last call. I do want to ask about the admin fees. It's been very difficult to get views from health system customers on where they believe this falls out, but we hear about the renewal process. It sounds like Q1 is relatively in line with expectations with the step down in Q2. I just want to check that assumption, given where it appears you're running for the year, that there's no change relative to the full year expectation of admin fees and any other nuances around that second half, first half.
spk09: Yes, sure, Eric. Thanks, first of all. Relative to the GPO business, the renewal process is going right according to plan in terms of the renewals that we're doing being in sync with our expectations of where the renewed contracts would come out. What I'd say from the standpoint of the overall GPO is we actually had a stronger underlying performance in the actual purchasing from our health systems in the first quarter, which led to a stronger Q1 than we thought. We are actually monitoring sort of elected procedures given the situation with Baxter and IV fluids and things like that, but overall, yes, on track and expect to continue to have fee share be in the low 60s throughout fiscal 2025 as we've guided to, and would expect that we'll continue to see good performance from our underlying purchasing through the supply chain services business.
spk02: Okay, and then Baxter was actually where I was going to go on the follow-up. Can you give us an update on what you've been doing to help offset the shortages and where we stand today as they're trying to get that up and running?
spk07: Yeah, so thank you, Eric. Whole bunch of stuff. They actually have a website out where they keep the healthcare community up to speed, and I think I saw something in the last couple of weeks where they got that factory back up and running. Not necessarily back to 100%, but it's back up and running. So there's been a number of things that we've been focused on. First of all, we've been working obviously with the health systems. We've been working with the federal government as well to figure out ways to mitigate the overall issue, and those things include coordinating with the FDA and HHS and the White House and other agencies to look at ways to fast-track the potential of bringing additional IV solution online. So that obviously is a big part of our discussion. Secondarily, we've been working with our health systems on looking at ways to conserve IV solution, and it's really interesting. In some of these cases, we might have found some opportunities where long-term there might be some practices that we can leverage that can drive more effective efficiency in the utilization of IV solutions. So conservation obviously is the second. And then the third is that we are working with other suppliers to look at where we can get IV solution that's either produced or get a potentially additional lines up and running to support the needs of the health system. So this is going to continue to play out over the end of this quarter and into the next quarter, but we're going to be focused on all three of those phases, working with obviously the federal government. Number two is looking at ways to conserve the supply that we have, and number three, we're going to look for additional capacity.
spk06: Thank you.
spk07: Thank you, Eric.
spk06: The next question comes from Michael Cherney with LRINK. Please go ahead.
spk05: Good morning, and I'll echo Eric's comments, Craig. It's been a great run, very helpful since before the IPO, and best of luck in your retirement and whatever you're doing next.
spk09: Thank you, Michael.
spk05: Maybe just a touch on the underlying core. Great to see the pull through on better spending. Obviously, I don't think anyone would disagree as a higher utilization environment. From macro level, beyond the renegotiations, what else do you feel like your customers are preparing for in terms of the sustainability of core utilization? How are they thinking through the impact both of proposed in-place and potentially in-place tariffs as they think through their purchasing decisions now and plan accordingly for whatever inventory levels they want to keep in a post-COVID world?
spk07: Yeah, so there's a lot there. Let me see if I can unpack some of that. From just a utilization standpoint of the health system in general, we're seeing pretty stable to slight increases of utilization. Now, that is being tampered by this IV solution issue. We're keeping an eye on that to see how the IV issue is having an impact on elective procedures and such. As it relates to the utilization of our contracts, one of the things, Michael, you know, we've been making significant investments in technologies to identify those areas where there's been spend that we don't have contracts for. Leveraging that information, leveraging that technology, we've been building out different forms of advanced technologies to identify where those high areas of spend are and to put contracts around that. We're going to obviously continue to do that and drive up, obviously, the opportunity for us to continue to contract in areas that historically we've not done or we've not delivered contracts. That's number one. Number two, health systems are really struggling right now with obviously the continual high cost of labor. What I am seeing as we're out having conversations with health systems is this idea that revenue seems to be growing, especially in those strong economic areas, but the profit isn't following. We're seeing this marginal pressure on these health systems. What we're really doubling down on is what can we be creating and what can we be driving that are really labor extenders? Leveraging our technology to help them be more efficient in terms of their back office, leveraging our technologies to drive more throughput through the health care system, identifying where they've got gaps or maybe areas that they've got high cost that we could help them manage through. All of those things are obviously building up into our strategy of how we're driving performance improvement today, but make no mistake, it's really all technology driven where identifying these opportunities and then wrapping around services to help drive these performance improvement solutions.
spk05: Mike, you alluded to my thoughts on my second question, and that's the idea of technology development. As you think through the adjustments you made on the portfolio, the changes on the Vestra of S2S Global, how do you think about your development pipeline both for internal technology, making the core administrative C capabilities and GPO better, and also areas, especially as health systems settle into this new normal, areas where you can be more helpful by further developing your performance services suite?
spk07: That's a great question. As you think about the evolution of our organic capital investment, we're continuing to think especially in the areas of HCC and prior authorization, how are we extending our current offerings? We're very, very good, for example, in radiology benefit management, and we're looking at other areas where we're now investing additional internal capital to grow where we have the opportunities to drive that technology into the health systems. That's number one. Number two, when you think about inorganic, as Craig said, we've always got that balanced approach to capital utilization. Number one, in supply chain, we want to continue to make investments to expand the portfolio. Where are those areas that we're not covering today? You've heard us talk about PPI and purchase services in the past, non-acute areas. Those are areas that we're going to continue to look for. Number two in the supply chain is that whole ordering platform. We do believe that to the degree that we can continue to evolve our offering there, where we can tee up appropriate pricing and appropriate alternatives to products, that there's a huge opportunity. We're going to continue to make investments there. Performance services, we talked a little bit about as I opened this up with HCC, prior authorization. We want to continue to make the appropriate investments there. Then finally, as we think about what we're doing in life sciences, continue to deploy capital to build out services around real-world evidence and those kinds of things for our life science companies. Craig?
spk09: Michael, this is Craig. One other point from an organic standpoint, as we've highlighted, we moved the historical Remitra platform into our supply chain services business this year. It really is about aligning our digital supply chain technology development to better align with the GPO and the technology enable the ability to get much tighter and fuller throughput of purchasing through the GPO, as well as potentially getting to the point that we actually have an ability to invoice suppliers for the administrative fees due to Premier versus historically relying on a supplier paid model.
spk05: Great. Thanks so much.
spk07: Thank you, Michael.
spk06: The next question comes from Jessica Tessin with Pepper Sandler. Please go ahead.
spk04: Hi. Thank you guys for taking the question. I wanted to start with the current portion of the liability related to the sale of future revenues to Omnia. Is that $41.3 million kind of reflecting the level above which Premier would be able to retain the associated operating income in FY25? And then just is that outperformance relative to the current portion of the liability included in your guidance or would that be upside?
spk09: Yeah. Thanks, Jessica. This is Craig. First of all, the current portion is just the anticipated amounts that we will need to actually pay back to Omnia during the given year, during fiscal 2025 as a result of their purchasing. So it's not above and beyond the expected purchasing. I think what you're referring to, just so others understand, is there's a baseline of $50 to $55 million of purchasing that we would expect to come through Omnia. Anything above and beyond that that comes through the Omnia purchasing off our portfolio, we get to retain 30% of that upside. We would anticipate that for this fiscal year, depending on how performance goes, that's only going to be a few million dollars in this initial year, given that it's early in the life of the Omnia relationship. So that nominal amount of a few million dollars would have been factored into our expectations for fiscal 2025 guidance, but it's not the magnitude of the whole current liability.
spk04: Okay. Got it. And then just another quick clarification question and then a real one. Why would the liability grow quarter over quarter from four Q to one Q?
spk09: It was due to the finalization of the Omnia transaction. So we actually, as I noted in my commentary, and you'll see in the release, we had a final payment of $42.3 million when we actually put a bow around the transaction in July. So that's why it went up. You would now expect to see it continue to come down quarter after quarter over the remaining life of the 10-year agreement.
spk04: Got it. And then my question is, is the increased purchasing you saw in the first quarter kind of indicative of Premier having reached a level of fee shareback rate that induces customer purchasing, or was it really more a matter of expanding categories and diversification of purchasing? Thanks.
spk09: Yeah, it's really- And
spk04: congratulations on your retirement.
spk09: Thank you, Jessica. I appreciate it. The first quarter performance is really much more about driving contract penetration and just undergoing pull through, leveraging our technology and our field resources to identify opportunities for savings as opposed to it being tied to any change in the fee share percentage.
spk07: Thank you, Jessica.
spk06: The next question comes from Kevin Caliendo with UBS. Please go ahead.
spk08: Thank you. Thanks for taking my question. And Craig, congratulations. Best of luck. And hopefully everything going forward will be relaxing, fun and enjoyable. Guys, my question really is on if there was any behavior ahead of tariffs or if you're expecting any behavior in terms of purchasing, people building inventories, you building inventories, if that affects how you think about cadence or anything else for the business. That was my first one. And we heard from a couple of supply chain companies that COVID impact came earlier this year because of timing, FDA, whatever, was wondering if that had an undue benefit for you in any way, shape or form in the quarter?
spk07: If that
spk08: impacts cadence.
spk07: No, no, sorry about that, Kevin. This is Mike. Hey, let me hit the COVID first. Just as a reminder, we didn't really see that kind of impact from COVID. And part of that, and this is why I was saying just as a reminder, flu doesn't necessarily drive a significant amount of supplies. So we didn't really see that impact from COVID this year. As it relates to the tariffs, that's a bit more of a complex question. So as you think about what our strategies have been over the last number of years, it's really as much as possible to try to reduce our dependence, obviously, in Southeast Asia and look for ways to create resiliency across the supply chain. And we did that. So we've created capabilities to produce masks. We've created domestically and near shore. We've done the same with isolation gowns and other products. So to some degree, we've been sort of building out the capability where tariffs wouldn't necessarily have a significant impact on a number of our categories. Having said that, we've not seen a significant pull on suppliers thinking through that there might be these tariffs that come out and that obviously increase the price of products. But instead, what we're seeing is organizations asking us to continue to look for more domestic and near shore capabilities where the tariffs may not have that significant of an impact. But so far, we've not seen some of the focus on building out inventory as a concern as it relates to tariffs.
spk08: Got it. If I can ask one quick follow-up. You talked a little bit about the IV bags and the weather. But how did it actually, as you think about the December quarter, how did it actually affect your numbers and did it in any way, shape, or form, your guidance, your expectations? Was there a drag because of this, like lower procedure volumes expected or anything like that?
spk09: Yeah, Kevin, it really varies depending on the status of where each individual health system was and the amount of product they had in inventory to manage procedures. Regionally, in various locations, we are aware that they had to be a little more conservative in terms of some of their elective procedures. But we aren't currently expecting that it will have a material impact on our second quarter performance.
spk08: Great. Thank you so much. Thank you.
spk06: The next question comes from Richard Close with Kenna Court Genuity. Please go ahead.
spk01: Hi, this is John Pinnion for Richard Close. Thanks for the question. I guess first question, with the GPO contract renewals, can you discuss how it's been potentially trying to cross-sell other services and as the renewals come up in this quarter, any movement there in that regard?
spk07: Yeah, so thank you. While we're going through this, obviously, it's an opportunity for us to spend time with the executive teams to ensure they understand the value that we can create. In fact, that's actually what's happening. As we're entering through these contract renewals, we see significant opportunities for us to cross-sell, obviously, our technology and our advisory services. Very, very high percent of these renewals are including that additional capability because at the end of the day, the healthcare systems are really looking for total value. We've been talking about that for years, but they're looking for total value in terms of what we can do to help them bend the cost of supplies for them and also look at ways to use our technologies to help them be a lot more efficient in how they're caring for patients.
spk01: All right, great, thanks. And then just one follow-up. The supply chain segment adjusted EBITDA margin was, if I'm getting this number correct, around 50%. I believe last quarter you were talking supply chain adjusted EBITDA being in the low to mid-40s. Is this a sustainable level or is there any commentary there of why it was above your expectation? Yeah,
spk09: as a reminder, we've discontinued the S2S global business in the first quarter, so that was a low margin business, so really affected the EBITDA margin for the segment. So the 51% that you saw in Q1 is indicative of sort of the range and level we would expect in fiscal 2025, so we would expect to have margins in that sort of 50% ballpark on a fiscal 2025 basis.
spk06: All right, great, thanks.
spk09: Thank
spk07: you.
spk06: The next question comes from Stephanie Davis with Barclays. Please go ahead.
spk03: Hey guys, thanks for taking my question. And Craig, you will be so missed.
spk09: Stephanie Glenn's going to do a fantastic job.
spk03: I'm sure you're not going to miss these earnings calls, but we're going to miss you a lot, and I hope you are in a stranger at happy hour.
spk09: Thank you very much.
spk03: So Mike, a lot of the prepared remarks, you're talking about AI, you call that license upside in supply chain of all segments, and then Craig called it having remittra in SCS. So is it right to think that now that you're kind of done with the reshuffling and gotten to the right businesses for your forward, you're going to lean into tech investments in the supply chain business? And if so, can you walk us through the top items within your wishlist?
spk07: Yes, yes, yes. I apologize if I, there must be a bit of a delay, Stephanie. I apologize if I jumped in there too early. But technology, supply chain, yeah. So we've been making that significant investment in e-invoicing and e-payables. What the e-invoicing capability allows for us to do, obviously, is to look at everything that a healthcare system buys and put contracts around that. So that's really, really important. Number two, last quarter we talked about the Allspire win. So that was a win where there were a number of healthcare systems that came together to pull their volumes to look at ways to reduce overall supply costs. Well, that technology can layer on top of these ERPs and identify where there's opportunities from a price parity standpoint, off-contract spend, all those kinds of things. So it is a critical differentiator, we believe, in the market. Not only to help us continue to drive and evolve, you know, obviously, our contract penetration models and obviously, therefore, more revenue, but also differentiate us for those entities that pull together healthcare systems as well as large IDNs that are still struggling with managing their entire invoice, you know, process. So very excited about that investment and looking for that forward, for that continue to penetrate the market.
spk03: I guess a follow-up on the supply chain side and the less tech-heavy part of it. You are seeing, I'm acknowledging that there's a co-option dynamic between GPOs and distributors, but you've seen a lot of distributors on the medical side lead into this prime vendor relationship and trying to have more of their own branded product sales. So was that kind of going a little bit more -to-head with your business? How are you thinking about those competitive dynamics and how are you working with these players as they try to be more of a direct relationship?
spk07: Yeah, so actually, we work very closely with the distributors. You know, as they're, you know, and this has been going on for a number of years, that they've been building out their private label programs and those kinds of things. Obviously, many of those are on our current contracts. So, you know, we obviously, they're a very, very important trading partner of ours. Number two, as we think about other areas, you know, we really do lean into the distributor partnerships that we have in the food program, for example. It truly does differentiate the value that we can create for our healthcare systems. And then similarly in the non-acute area, we have, you know, very strong partnerships there with the distributor where we create differentiated value for those non-acute players in healthcare. So, you know, Stephanie, it's kind of interesting depending on where they play within the healthcare ecosystem. You know, we have a, you know, basically a different playbook, but we do want to leverage their scale where it makes sense.
spk03: Super helpful. Thank you, guys. Craig, come to Miami.
spk09: Yep. Thanks, Stephanie.
spk06: This concludes our question and answer session and premieres fiscal 2025 first quarter conference call. Thank you for attending today's presentation. You may now disconnect.
Disclaimer